Anupam Rasayan India Ltd · ANURAS · Speciality Chemicals · price as of the 18 November 2026 close, updated every trading day · results updated weekly · research updated 6 November 2026
Anupam Rasayan India share price today: ₹1,321.10 at the close on 18 November 2026, up 6.0% in a year. Anupam Rasayan India (ANURAS) is worth ₹15,036 crore, trades at a P/E of 83.4 and has closed between ₹1,101.60 and ₹1,376.00 over the past 52 weeks. Latest change: revenue up on a year earlier for 8 quarters in a row.
Anupam Rasayan India Ltd's earnings have grown faster than its share price. Earnings per share grew +16.4% in a year while the price moved +6.0%.
The main question: promoters moved −2.2 percentage points over 8 quarters while the business went the other way.
The price has been falling for 7 weeks, and the P/E is higher than 55% of its own last 5.6 years. Over the last four quarters, results have been improving, with profit +14.0% on a year earlier, and 66% of the last 3 years' profit came in as cash. What will decide it: whether the owners’ moves turn back in line with the business.
Left out of this page: Its two data sources disagree by up to 63% on reported income across 17 comparable periods, so nothing from the second source is shown here. That is why the PEG ratio and its quarterly curve, the yearly return-on-capital-used (ROIC) line, the total-debt and debt-to-equity series and the F-score and the return-on-capital-used (ROIC) reading are missing. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. The quarterly history also starts where the main source starts: 5 earlier quarters from the second source are not added in front of it. Adding to a profit history needs a source that has been checked.
What is the Anupam Rasayan India share price today?
Anupam Rasayan India Ltd's share price was ₹1,321.10 at the close on 18 November 2026. It has been falling for 7 weeks. That is 9.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,102 and ₹1,376, and at that close it sat 80% of the way up from that low.
A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Anupam Rasayan India Ltd is in stage 4. The phase helps read everything below.
Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row.
Week by week since 2021: did it beat the NIFTY 500 over the past 13 weeks?
Ahead in 124 of 290 weeks
| Week | 13-week return vs NIFTY 500 |
|---|---|
| 26 Mar 2021 | no NIFTY 500 reading |
| 1 Apr 2021 | no NIFTY 500 reading |
| 9 Apr 2021 | no NIFTY 500 reading |
| 16 Apr 2021 | no NIFTY 500 reading |
| 23 Apr 2021 | no NIFTY 500 reading |
| 30 Apr 2021 | no NIFTY 500 reading |
| 7 May 2021 | no NIFTY 500 reading |
| 14 May 2021 | no NIFTY 500 reading |
| 21 May 2021 | no NIFTY 500 reading |
| 28 May 2021 | no NIFTY 500 reading |
| 4 Jun 2021 | no NIFTY 500 reading |
| 11 Jun 2021 | no NIFTY 500 reading |
| 18 Jun 2021 | no NIFTY 500 reading |
| 25 Jun 2021 | +38.9% |
| 2 Jul 2021 | +38.5% |
| 9 Jul 2021 | +38.3% |
| 16 Jul 2021 | +28.7% |
| 23 Jul 2021 | +16.8% |
| 30 Jul 2021 | +5.9% |
| 6 Aug 2021 | −12.3% |
| 13 Aug 2021 | −10.1% |
| 20 Aug 2021 | −13.1% |
| 27 Aug 2021 | −11.4% |
| 3 Sep 2021 | −12.1% |
| 9 Sep 2021 | −12.8% |
| 17 Sep 2021 | −8.5% |
| 24 Sep 2021 | −10.4% |
| 1 Oct 2021 | −8.2% |
| 8 Oct 2021 | −17.1% |
| 14 Oct 2021 | −14.9% |
| 22 Oct 2021 | −7.8% |
| 29 Oct 2021 | +0.1% |
| 4 Nov 2021 | +2.8% |
| 12 Nov 2021 | −2.0% |
| 18 Nov 2021 | +1.9% |
| 26 Nov 2021 | +3.7% |
| 3 Dec 2021 | +5.4% |
| 10 Dec 2021 | +7.4% |
| 17 Dec 2021 | +13.2% |
| 24 Dec 2021 | +22.7% |
| 31 Dec 2021 | +26.9% |
| 7 Jan 2022 | +30.9% |
| 14 Jan 2022 | +25.6% |
| 21 Jan 2022 | +26.5% |
| 28 Jan 2022 | +24.1% |
| 4 Feb 2022 | +28.9% |
| 11 Feb 2022 | +22.7% |
| 18 Feb 2022 | +16.3% |
| 25 Feb 2022 | +12.4% |
| 4 Mar 2022 | +6.6% |
| 11 Mar 2022 | +11.6% |
| 17 Mar 2022 | +4.3% |
| 25 Mar 2022 | −4.0% |
| 1 Apr 2022 | −16.7% |
| 8 Apr 2022 | −18.1% |
| 13 Apr 2022 | −10.8% |
| 22 Apr 2022 | −13.0% |
| 29 Apr 2022 | −15.6% |
| 6 May 2022 | −13.1% |
| 13 May 2022 | −7.9% |
| 20 May 2022 | −11.9% |
| 27 May 2022 | −16.8% |
| 3 Jun 2022 | −16.3% |
| 10 Jun 2022 | −25.2% |
| 17 Jun 2022 | −24.7% |
| 24 Jun 2022 | −19.8% |
| 1 Jul 2022 | −14.0% |
| 8 Jul 2022 | −16.1% |
| 15 Jul 2022 | −6.9% |
| 22 Jul 2022 | −3.4% |
| 29 Jul 2022 | −3.0% |
| 5 Aug 2022 | −12.3% |
| 12 Aug 2022 | −18.7% |
| 19 Aug 2022 | −10.3% |
| 26 Aug 2022 | +0.5% |
| 2 Sep 2022 | +4.1% |
| 9 Sep 2022 | +14.1% |
| 16 Sep 2022 | +17.6% |
| 23 Sep 2022 | +12.0% |
| 30 Sep 2022 | +10.1% |
| 7 Oct 2022 | +9.4% |
| 14 Oct 2022 | −8.5% |
| 21 Oct 2022 | −10.4% |
| 28 Oct 2022 | −6.0% |
| 4 Nov 2022 | −6.6% |
| 11 Nov 2022 | −4.1% |
| 18 Nov 2022 | −4.3% |
| 25 Nov 2022 | −8.8% |
| 2 Dec 2022 | −10.9% |
| 9 Dec 2022 | −11.2% |
| 16 Dec 2022 | −11.1% |
| 23 Dec 2022 | −14.4% |
| 30 Dec 2022 | −13.7% |
| 6 Jan 2023 | −7.7% |
| 13 Jan 2023 | −10.7% |
| 20 Jan 2023 | −15.4% |
| 27 Jan 2023 | −21.1% |
| 3 Feb 2023 | −19.3% |
| 10 Feb 2023 | −13.1% |
| 17 Feb 2023 | −11.5% |
| 24 Feb 2023 | −3.7% |
| 3 Mar 2023 | +9.7% |
| 10 Mar 2023 | +11.5% |
| 17 Mar 2023 | +16.1% |
| 24 Mar 2023 | +34.7% |
| 31 Mar 2023 | +33.1% |
| 6 Apr 2023 | +41.0% |
| 13 Apr 2023 | +49.3% |
| 21 Apr 2023 | +66.4% |
| 28 Apr 2023 | +87.0% |
| 5 May 2023 | +94.2% |
| 12 May 2023 | +85.9% |
| 19 May 2023 | +89.1% |
| 26 May 2023 | +80.6% |
| 2 Jun 2023 | +44.9% |
| 9 Jun 2023 | +37.0% |
| 16 Jun 2023 | +32.4% |
| 23 Jun 2023 | +9.2% |
| 30 Jun 2023 | +6.2% |
| 7 Jul 2023 | −7.6% |
| 14 Jul 2023 | −9.1% |
| 21 Jul 2023 | −21.4% |
| 28 Jul 2023 | −24.9% |
| 4 Aug 2023 | −28.4% |
| 11 Aug 2023 | −27.5% |
| 18 Aug 2023 | −30.0% |
| 25 Aug 2023 | −24.0% |
| 1 Sep 2023 | −18.1% |
| 8 Sep 2023 | −19.4% |
| 15 Sep 2023 | −22.4% |
| 22 Sep 2023 | −23.1% |
| 29 Sep 2023 | −19.3% |
| 6 Oct 2023 | −14.7% |
| 13 Oct 2023 | −16.9% |
| 20 Oct 2023 | −14.9% |
| 27 Oct 2023 | −11.7% |
| 3 Nov 2023 | −3.3% |
| 12 Nov 2023 | −5.1% |
| 17 Nov 2023 | −6.3% |
| 24 Nov 2023 | −11.3% |
| 1 Dec 2023 | −5.2% |
| 8 Dec 2023 | −1.7% |
| 15 Dec 2023 | +2.3% |
| 22 Dec 2023 | +4.3% |
| 29 Dec 2023 | +6.5% |
| 5 Jan 2024 | +6.9% |
| 12 Jan 2024 | −5.0% |
| 20 Jan 2024 | −4.4% |
| 25 Jan 2024 | −2.4% |
| 2 Feb 2024 | −12.2% |
| 9 Feb 2024 | −15.9% |
| 16 Feb 2024 | −17.3% |
| 23 Feb 2024 | −16.1% |
| 2 Mar 2024 | −17.8% |
| 7 Mar 2024 | −18.9% |
| 15 Mar 2024 | −16.1% |
| 22 Mar 2024 | −16.9% |
| 28 Mar 2024 | −21.5% |
| 5 Apr 2024 | −22.3% |
| 12 Apr 2024 | −14.8% |
| 19 Apr 2024 | −9.6% |
| 26 Apr 2024 | −20.3% |
| 3 May 2024 | −17.4% |
| 10 May 2024 | −17.0% |
| 18 May 2024 | −17.9% |
| 24 May 2024 | −24.6% |
| 31 May 2024 | −24.1% |
| 7 Jun 2024 | −24.3% |
| 14 Jun 2024 | −25.5% |
| 21 Jun 2024 | −23.5% |
| 28 Jun 2024 | −23.5% |
| 5 Jul 2024 | −25.6% |
| 12 Jul 2024 | −24.6% |
| 19 Jul 2024 | −22.9% |
| 26 Jul 2024 | −18.6% |
| 2 Aug 2024 | −16.4% |
| 9 Aug 2024 | −13.2% |
| 16 Aug 2024 | −6.9% |
| 23 Aug 2024 | −6.6% |
| 30 Aug 2024 | −10.4% |
| 6 Sep 2024 | −8.8% |
| 13 Sep 2024 | −10.1% |
| 20 Sep 2024 | −12.8% |
| 27 Sep 2024 | −13.3% |
| 4 Oct 2024 | −4.5% |
| 11 Oct 2024 | −4.4% |
| 18 Oct 2024 | −10.0% |
| 25 Oct 2024 | −8.6% |
| 1 Nov 2024 | −5.0% |
| 8 Nov 2024 | −4.3% |
| 14 Nov 2024 | −3.9% |
| 22 Nov 2024 | −1.1% |
| 29 Nov 2024 | −1.5% |
| 6 Dec 2024 | −3.0% |
| 13 Dec 2024 | +0.5% |
| 20 Dec 2024 | +3.8% |
| 27 Dec 2024 | +6.5% |
| 3 Jan 2025 | +1.1% |
| 10 Jan 2025 | +1.6% |
| 17 Jan 2025 | +2.6% |
| 24 Jan 2025 | +4.9% |
| 1 Feb 2025 | −0.1% |
| 7 Feb 2025 | +3.6% |
| 14 Feb 2025 | −2.2% |
| 21 Feb 2025 | −5.8% |
| 28 Feb 2025 | −1.3% |
| 7 Mar 2025 | +18.7% |
| 13 Mar 2025 | +18.0% |
| 21 Mar 2025 | +11.9% |
| 28 Mar 2025 | +11.2% |
| 4 Apr 2025 | +13.2% |
| 11 Apr 2025 | +6.5% |
| 17 Apr 2025 | +16.2% |
| 25 Apr 2025 | +22.2% |
| 2 May 2025 | +23.9% |
| 9 May 2025 | +22.3% |
| 16 May 2025 | +29.6% |
| 23 May 2025 | +36.6% |
| 30 May 2025 | +44.2% |
| 6 Jun 2025 | +20.0% |
| 13 Jun 2025 | +28.3% |
| 20 Jun 2025 | +38.8% |
| 27 Jun 2025 | +38.8% |
| 4 Jul 2025 | +35.6% |
| 11 Jul 2025 | +50.0% |
| 18 Jul 2025 | +35.9% |
| 25 Jul 2025 | +28.4% |
| 1 Aug 2025 | +27.1% |
| 8 Aug 2025 | +21.8% |
| 14 Aug 2025 | +23.2% |
| 22 Aug 2025 | +19.5% |
| 29 Aug 2025 | +13.9% |
| 5 Sep 2025 | +8.0% |
| 12 Sep 2025 | −2.6% |
| 19 Sep 2025 | −6.8% |
| 26 Sep 2025 | +0.8% |
| 3 Oct 2025 | −2.0% |
| 10 Oct 2025 | −2.1% |
| 17 Oct 2025 | −8.8% |
| 24 Oct 2025 | −7.7% |
| 31 Oct 2025 | −10.1% |
| 7 Nov 2025 | −8.2% |
| 14 Nov 2025 | −12.5% |
| 21 Nov 2025 | +6.8% |
| 28 Nov 2025 | +1.6% |
| 5 Dec 2025 | +9.2% |
| 12 Dec 2025 | +16.3% |
| 19 Dec 2025 | +22.9% |
| 26 Dec 2025 | +15.3% |
| 2 Jan 2026 | +17.1% |
| 9 Jan 2026 | +16.6% |
| 16 Jan 2026 | +24.1% |
| 23 Jan 2026 | +16.9% |
| 1 Feb 2026 | +16.6% |
| 6 Feb 2026 | +21.8% |
| 13 Feb 2026 | +26.7% |
| 20 Feb 2026 | +4.7% |
| 27 Feb 2026 | +4.6% |
| 6 Mar 2026 | +5.0% |
| 13 Mar 2026 | +4.3% |
| 20 Mar 2026 | +3.9% |
| 27 Mar 2026 | +5.0% |
| 2 Apr 2026 | +8.6% |
| 10 Apr 2026 | +3.0% |
| 17 Apr 2026 | +0.5% |
| 24 Apr 2026 | +9.6% |
| 30 Apr 2026 | +11.5% |
| 8 May 2026 | +5.7% |
| 15 May 2026 | +6.3% |
| 22 May 2026 | +9.5% |
| 29 May 2026 | +6.6% |
| 4 Jun 2026 | +7.7% |
| 5 Jun 2026 | +2.5% |
| 9 Jun 2026 | −4.8% |
| 10 Jun 2026 | −4.4% |
| 12 Jun 2026 | −9.1% |
| 17 Jun 2026 | −2.9% |
| 19 Jun 2026 | −2.0% |
| 24 Jun 2026 | −6.9% |
| 25 Jun 2026 | −7.0% |
| 1 Jul 2026 | −8.2% |
| 3 Jul 2026 | −11.1% |
| 10 Jul 2026 | −10.3% |
| 17 Jul 2026 | −5.0% |
| 24 Jul 2026 | −9.3% |
| 31 Jul 2026 | −13.5% |
| 7 Aug 2026 | −9.1% |
| 14 Aug 2026 | −9.3% |
| 21 Aug 2026 | −4.6% |
| 28 Aug 2026 | −4.3% |
| 4 Sep 2026 | −3.5% |
| 11 Sep 2026 | −3.7% |
| 18 Sep 2026 | −4.1% |
| 25 Sep 2026 | −3.2% |
| 1 Oct 2026 | −2.2% |
| 9 Oct 2026 | −4.3% |
| 16 Oct 2026 | −2.6% |
| 23 Oct 2026 | −5.4% |
| 30 Oct 2026 | +1.3% |
| 6 Nov 2026 | −3.0% |
| 8 Nov 2026 | −1.4% |
| 13 Nov 2026 | +3.7% |
| 18 Nov 2026 | +3.9% |
Over the last 5.6 years the share price moved +167% while the NIFTY 500 moved +95%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.
This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.
What changed at Anupam Rasayan India this quarter?
Revenue up on a year earlier for 8 quarters in a row
In the September 2026 quarter revenue was ₹806 crore, +10.3% on a year earlier.
Why: Revenue rose because the company sold more performance materials and had a better mix of products.
Next results: check whether second half revenue shows the full contribution from all four businesses.
From the earnings call on 6 Nov 2026.
Highest quarterly profit in 14 quarters
Profit of ₹65 crore in the September 2026 quarter is the highest of the last 14 quarters.
Why: Profit rose because the company had a bigger share of performance materials and a better product mix.
Next results: check whether the stronger profit margin lasts, since management kept its margin aim unchanged and expects more pharma and performance materials in the mix.
From the earnings call on 6 Nov 2026.
The 200-day average is the share's average price over about ten months. It closed at ₹1300.6 on 13 Nov 2026, above that average of ₹1211.
What are Anupam Rasayan India's latest quarterly results?
For July to September 2026 (the quarter ended 30 September 2026), Anupam Rasayan India reported revenue of ₹806 crore, up 10.3% from ₹731 crore a year earlier, and a profit of ₹65.0 crore, up 14.0% from ₹57.0 crore.
Anupam Rasayan India results: July to September 2026 against a year earlier
| Measure | July to September 2026 | July to September 2025 | Change |
|---|---|---|---|
| Revenue | ₹806 crore | ₹731 crore | +10.3% |
| Profit | ₹65.0 crore | ₹57.0 crore | +14.0% |
| Earnings per share | ₹4.39 | ₹3.90 | +12.6% |
| Operating margin | 23.2% | 18.6% | +4.6 points |
The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).
Anupam Rasayan India's management discussed these results on a call held on 6 November 2026; what it said is further down this page.
From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.
What is the Anupam Rasayan India share price history?
Anupam Rasayan India closed at ₹1,321.10 on 18 November 2026, up 6.0% from ₹1,246.80 a year earlier (21 November 2025) and up 62.1% over five years. Its highest weekly close since March 2021 was ₹1,376.00 on 15 May 2026.
Anupam Rasayan India share price: then and now
| When | Close | Change to 18 Nov 2026 |
|---|---|---|
| 1 week ago · 11 Nov 2026 | ₹1,191.90 | +10.8% |
| 1 month ago · 19 Oct 2026 | ₹1,109.70 | +19.1% |
| 6 months ago · 15 May 2026 | ₹1,376.00 | −4.0% |
| 1 year ago · 21 Nov 2025 | ₹1,246.80 | +6.0% |
| 3 years ago · 17 Nov 2023 | ₹931.60 | +41.8% |
| 5 years ago · 18 Nov 2021 | ₹815.05 | +62.1% |
| Earliest and lowest weekly close in our records · 26 Mar 2021 | ₹495.70 | +166.5% |
| Highest weekly close since March 2021, also the 52-week high · 15 May 2026 | ₹1,376.00 | −4.0% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹1,101.60 | +19.9% |
Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.
303 weekly closes from 26 March 2021 to 18 November 2026.
What is the latest news on Anupam Rasayan India?
18 Nov 2026: Anupam Rasayan India closed at ₹1,321.10, up 10.8% on the week and up 19.1% on the month. 6 Nov 2026: Anupam Rasayan India held its results call for July to September 2026. Management guided: H2FY27 consolidated revenue around ₹2,400-2,500 crore implying ₹4,800-5,000 crore annualized run-rate.
Earlier
- Results for July to September 2026: Revenue up 10.3% and profit up 14.0% on a year earlier.
- 18 Sep 2026: ex-date for a dividend of ₹1.50 a share.
What dividend does Anupam Rasayan India pay?
Anupam Rasayan India paid ₹1.50 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.11% at the ₹1,321.10 close on 18 November 2026. The last was a dividend of ₹1.50 a share, ex-date 18 September 2026.
Anupam Rasayan India dividends since 1 April 2021
| Ex-date | Dividend per share | Type | Record date |
|---|---|---|---|
| 18 Sep 2026Dividend | ₹1.50 | Dividend | same day |
| 21 Jul 2025Interim | ₹0.75 | Interim | same day |
| 17 Sep 2024Dividend | ₹0.75 | Dividend | 18 Sep 2024 |
| 20 Nov 2023Interim | ₹0.50 | Interim | same day |
| 15 May 2023Interim | ₹1.50 | Interim | same day |
| 8 Feb 2023Interim | ₹0.60 | Interim | same day |
| 2 Sep 2022Dividend | ₹1 | Dividend | 5 Sep 2022 |
| 3 Aug 2022Interim | ₹0.40 | Interim | 4 Aug 2022 |
| 17 Nov 2021Interim | ₹0.50 | Interim | 18 Nov 2021 |
| 15 Sep 2021Dividend | ₹0.50 | Dividend | 16 Sep 2021 |
Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date.
Yes. Anupam Rasayan India Ltd paid out 10% of its profit as dividends in FY26, and it paid a dividend in 6 of its last 12 reported years.
From the exchange corporate-actions record, read 18 November 2026.
What did Anupam Rasayan India management say on the latest results call?
On the call for July to September 2026, held on 6 November 2026, Anupam Rasayan India's management guided: H2FY27 consolidated revenue around ₹2,400-2,500 crore implying ₹4,800-5,000 crore annualized run-rate.
“As the overall contribution from pharmaceuticals and performance materials increases and becomes a larger share of the group's revenue mix, we expect revenue cyclicality to reduce over the next 4-8 quarters.”Amit Khurana, on the call for July to September 2026
What management guided
- Organic revenue growth 20-25% over near-term 3-5 year period planned.
- United States metal pact balance ₹100-150 crore this year with monthly run-rate doubling over next 12-18 months.
- Bliss steady-state operating margin 22-24% aligned to consolidated average goal.
- Long-term agreement revenue this year 1.8-2.0 times prior base of around ₹350 crore.
Management’s own plans and goals, from our notes of the call. A plan is not a result.
Source: the call transcript.
From the call for July to September 2026, 6 November 2026.
What to watch in Anupam Rasayan India's next results?
When Anupam Rasayan India reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Consolidated second-half revenue on full four-entity contribution scale-up - check print against flagged stronger-half goal.
Management raised each of these on the latest results call.
- Consolidated second-half revenue on full four-entity contribution scale-up - check print against flagged stronger-half goal.
- United States metal supply ramp from imminent start - check monthly volumes against flagged balance and doubling path.
- Bliss first full-quarter contribution with utilization lift - check operating print against flagged synergy window and margin framework.
Which stock lists is Anupam Rasayan India on?
Anupam Rasayan India is on 2 of our India lists: Momentum stocks and Small & mid cap stocks.
Is Anupam Rasayan India profitable?
Anupam Rasayan India Ltd earned ₹65.0 Cr of net profit in the Sep 2026 quarter, +14.0% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹222 Cr. Over 10 years profit has grown 20.0% a year on average. The same quarter a year earlier earned ₹57.0 Cr.
Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.
The Sep 2026 quarter's profit is 8.1% of that quarter's revenue.
For the full year, FY26 profit was ₹222 Cr (+38.7% on the year before).
Why profit moved: revenue changed +10.3% on a year earlier and the margin moved +4.6 percentage points. Most of the change came from keeping more of each sale.
On average over the last four quarters, profit changed +5.5% and revenue +25.9%. Profit is growing slower than sales: rising costs are taking part of the growth.
How much revenue does Anupam Rasayan India make, and is it growing?
Anupam Rasayan India Ltd reported ₹806 Cr of revenue in the Sep 2026 quarter, +10.3% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 10 years it has grown 24.1% a year on average. The last full year, FY26, came in at ₹2,365 Cr.
Revenue is everything the company billed its customers in the period.
Why this happened. Jayhawk provides what Anupam previously lacked: direct US onshore manufacturing validated with American customers. This addresses the critical barrier for large multinational customers who demand 'strong, credible full supply chain solutions, not import-and-process models.' Jayhawk brings established customer relationships in semiconductor, aerospace, pharma, and EV/automotive end-markets. The strategic logic is strong: most competitors cannot offer an integrated India→US fluorine supply chain. The caution: EPS accretion claim is management assertion, unverified until Q4 FY26 actuals.
The last four reported quarters add to ₹2,609 Cr.
FY26 revenue was ₹2,365 Cr, +64.6% on the year before.
Recent pace: the last four quarters grew +25.9% on average, against 24.1% a year over the longer run, so this year is growing faster than its own long-run rate.
Is growth speeding up? Revenue over the last 12 months grew +23.8%, against +44.8% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +5.0%, against +46.2% a year (rolling over).
Watch next
- Metric
- Jayhawk Acquisition, US Onshore Manufacturing
- Threshold
- Q4 FY26 WC days actual (must show progress below 230 days to validate FY27 goal)
- Which result
- the next result
How much of every ₹100 of sales does Anupam Rasayan India keep?
Anupam Rasayan India Ltd's operating margin was 23.2% in the Sep 2026 quarter, 4.6 percentage points higher than the same quarter a year ago. Across 12 years it has been between 18.5% and 28.4%. The latest quarter is within that range.
Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.
Why this happened. The pharma strategy goals the KSM (Key Starting Material) space where Indian players have not yet built manufacturing depth. Anupam launched 9 molecules in FY25 (5 pharma) and 17 new molecules over 18 months, these are now ramping to revenue. High-value molecules across CNS, statins, and infectious disease create long-term supply agreements (3-5 year customer validation cycles). The 85% YoY growth is multi-quarter and structural, not a one-off.
Why the margin moved: operating margin changed +4.7 percentage points on the year while gross margin changed +14.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged.
Watch next
- Metric
- Pharma Segment Ramp (KSM / API input substitution)
- Threshold
- Q4 FY26 WC days actual (must show progress below 230 days to validate FY27 goal)
- Which result
- the next result
Is Anupam Rasayan India's profit turning into cash?
Over the last 3 years, 66% of Anupam Rasayan India Ltd's reported profit came in as cash from its operations, so most of the profit is real cash. In FY26 it brought in ₹334 Cr of operating cash against ₹222 Cr of profit.
The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.
After ₹555 Cr of spending on assets, free cash was −₹221 Cr: it spent more than its operations brought in.
Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.
Why 66% of profit came in as cash: the cash cycle got 31 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. When less than 70% of profit comes in as cash, it is the thing to watch on this page.
What to look at next: the bigger use of cash is spending on new assets, at 5.2× depreciation over three years. The next section checks what that spending is building.
Where does Anupam Rasayan India's cash go?
Anupam Rasayan India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 377 days in FY26, down from 408 days in FY21. It spent ₹1,681 Cr on assets over the last 3 years. Customers take 148 days to pay, and stock sits for 490 days on average.
Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.
At FY26 sales of ₹2,365 Cr, each day of that cycle ties up about ₹6.5 Cr, so roughly ₹2,443 Cr is tied up in the business at any time.
FY26: customers took 148 days to pay and stock sat for 490 days, about 16.1 months of sales sitting as stock, for a full cycle of 377 days, shorter than FY21's 408.
The full loop: cash goes out to suppliers and production on day 0. Stock sits for 490 days. Customers pay about 148 days after that. Suppliers are paid at 261 days. Together that makes the 377-day cycle.
Spending on assets: ₹1,681 Cr over the last 3 years, against ₹322 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹114 Cr (FY26): assets paid for that are not earning yet.
In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.
What is Anupam Rasayan India's P/E ratio, and how does it compare with its own history?
Anupam Rasayan India Ltd's P/E is 83.4×, in the middle of its own history: higher than 55% of past readings. Its usual P/E (the middle reading) is 80.8×, over 5.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.
P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.
Why the multiple is where it is: over the past year earnings per share moved +16.4% while the price moved +6.0%. Earnings did better than the price, which pulled the multiple down within its own range.
Where the price move came from: over 5 years the price moved +10.1% a year; about +6.5% a year came from earnings growth and about +3.6 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.
In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.
The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 63% on reported income across 17 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.
Is the Anupam Rasayan India business getting better or worse?
Anupam Rasayan India Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: revenue growth has eased from +66.5% at its peak to +23.8%, but the business is still expanding, with ROCE falling at 7.6% (four quarters to Sep 2026). This is based on 10 quarters of 4 measures, with some gaps.
Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.
Why it matters: when the lines disagree, each line above matters more than any single label.
The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.
This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.
Compound annual growth rate (%)
Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.
| Measure | 1yr | 3yr | 5yr | 10yr |
|---|---|---|---|---|
| Revenue | +64.6% | +13.9% | +23.9% | +24.1% |
| Profit | +38.7% | +0.8% | +26.0% | +20.0% |
| EPS | +76.0% | −3.9% | +16.2% | +7.5% |
| Share price | +6.0% | +12.3% | +10.1% | — |
What is the Anupam Rasayan India story, and has it been checked?
Anupam Rasayan India Ltd's story is not scored yet against the checks our research set on 17 May 2026. Where it sits in its own cycle: recovery mid.
NOT YET CHECKED
Our read, 17 May 2026. A fluorine chemistry platform in mid-transition, revenue inflecting hard but capital returns still depressed, with a US acquisition that could either unlock the next leg or drag integration costs.
From the numbers. EPS…
From the price. Price stage 4, week 7, above its 200-day line, relative strength rising.
Where they disagree. EPS recovery is real (PAT +71% YoY in 9M FY26) but ROCE and ROE remain depressed at 7.33% and 3.32% respectively. DII stake-cutting adds a cautionary institutional signal.
What is not proven yet. Management has now missed the WC goal twice (FY26 goal pushed to FY27). At 250 days, Rs 730 Cr net debt, and Rs 35-36 Cr/quarter interest, FCF remains deeply negative and growth requires dilution or further debt.
The test written in advance. Working Capital at 250 days, Cash Flow Drag Persists. Measured by: Working Capital at 250 days, Cash Flow Drag Persists Q4 FY26 WC days actual (must show progress below 230 days to validate FY27 goal) by the next result.
The test written in advance. PAT Margin Dilution from New Molecule Ramp. Measured by: PAT Margin Dilution from New Molecule Ramp Q4 FY26 and Q1 FY27 OPM trajectory, must recover toward 27-28% as mix shifts to higher-margin molecules by the next result.
The test written in advance. Jayhawk Integration Risk. Measured by: Jayhawk Integration Risk Q4 FY26 concall: confirmation of closing date, Jayhawk revenue contribution, and integration timeline by the next result.
What the company does. 9M FY26 revenue Rs 1,730 Cr (+84% YoY) after FY25 contraction; Pharma +85% and Performance Materials +245% driving the recovery, with the agro segment also bouncing back. Jayhawk (US specialty chemicals) acquisition closing FY26-end creates a full-stack fluorine supply chain India→US; EPS accretive from day one per management, unverified until Q4 FY26 actuals land.
The key numbers to watch, and the level that would change the picture
| Measure | Now | Why it matters |
|---|---|---|
| Pharma Segment Ramp (KSM / | HIGH | Pharma revenue +85% YoY in 9M FY26; 30+ molecules in R&D/pilot including Apixaban, Statins, Sitagliptin, Venetoclax. Input… |
| Performance Materials, Defense… | HIGH | Performance Materials +245% YoY in 9M FY26 (17% of revenue); 35+ molecules in development for semiconductors, aerospace, EV… |
| Jayhawk Acquisition, US Onshore… | HIGH | 100% acquisition of US-based Jayhawk Fine Chemicals closing within weeks of Feb 2026 call. Creates Tanfac→Anupam→Jayhawk full… |
| Order Book Conversion, Rs 14,646 Cr LOI… | MEDIUM HIGH | Rs 14,646 Cr order book (4-10 year spread); Rs 3,100 Cr already commercialized (>20% of FY25 revenue); Rs 250+ Cr from LOIs and… |
| Working Capital Normalization (PAT… | MEDIUM | WC reduction from 250 days to <180 days by FY27 would release Rs 400-450 Cr cash and reduce interest expense by Rs 30-40… |
| Japan Deepening (17% of revenue, aiming for… | MEDIUM | Japan 17% of Q3 FY26 revenue; aiming for 20%+ in FY26 via new customer additions and molecule expansion. MPA signed with Japan… |
Everything further down this page is evidence for or against these.
FY25-Q4FY26-Q3
- 1 · Operating leveragequiet
- 2 · Value-added mixbuilding
- 3 · Management changebuilding
- 4 · Paying down debtquiet
- 5 · Regulatory approvalquiet
- 6 · Order-book winsbuilding
- 7 · Consolidationbuilding
- 8 · Demerger or value unlockquiet
- 9 · Buybackquiet
- 10 · New geographiesbuilding
- 11 · More business from existing customersquiet
- 12 · New product launchquiet
- 13 · Mandatory normsquiet
- 14 · A bigger market to servequiet
- 15 · Market-share gainsquiet
- 16 · Asset qualityquiet
Lever 2 · Value-added mix: building. Pharma revenue +85% YoY in 9M FY26; 30+ molecules in R&D/pilot including Apixaban, Statins, Sitagliptin, Venetoclax. Input substitution for KSMs not yet addressed by Indian players. What proves it keeps working: Pharma Segment Ramp (KSM / API input substitution). It stops working if Q4 FY26 WC days actual (must show progress below 230 days to validate FY27 goal).
Lever 3 · Management change: building. Performance Materials +245% YoY in 9M FY26 (17% of revenue); 35+ molecules in development for semiconductors, aerospace, EV, automotive. Dual LiPF6 LOIs with E-Lyte Innovations (EU) and Elementium (US) signed. What proves it keeps working: Performance Materials, Defense, Electronics, EV Chemistry.
Lever 10 · New geographies: building. 100% acquisition of US-based Jayhawk Fine Chemicals closing within weeks of Feb 2026 call. Creates Tanfac→Anupam→Jayhawk full fluorine supply chain. EPS accretive day one per management. What proves it keeps working: Jayhawk Acquisition, US Onshore Manufacturing.
Lever 6 · Order-book wins: building. Rs 14,646 Cr order book (4-10 year spread); Rs 3,100 Cr already commercialized (>20% of FY25 revenue); Rs 250+ Cr from LOIs and contracts converted in 9M FY26. What proves it keeps working: Order Book Conversion, Rs 14,646 Cr LOI Pipeline.
Sources: our stock research file (17 May 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
The whole page in one table. Each row links to its section.
| Section | Where it is now | The one thing to watch next |
|---|---|---|
| Margin | 23% | Pharma Segment Ramp (KSM / API input substitution) |
| Ownership | see the section | Performance Materials, Defense, Electronics, EV Chemistry |
| Revenue | ₹806 Cr | Jayhawk Acquisition, US Onshore Manufacturing |
Did Anupam Rasayan India management deliver what it promised?
What Anupam Rasayan India Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Jayhawk Consolidation Period Does Not Reconcile · 6 November 2026. The May 2026 call said Jayhawk had contributed only 1 month and 2 days in FY26 and that its full contribution would be visible in FY27; the Aug 2026 call characterized FY27 as the first full year of consolidation. Yet the Nov 2026 Q2 and H1 FY27 call still described Jayhawk as consolidated for only 4 months, which does not reconcile with the intervening Q1 and Q2 and could materially distort consolidated revenue and run-rate assumptions.
Working Capital Is Above Prior Pro Forma Range · 6 November 2026. The May 2026 call described consolidated working capital of 215-220 days on a pro forma basis and 240-250 days excluding Jayhawk, while the Nov 2026 call reported 271 days even after excluding the Bliss balance sheet. Management explained the Bliss consolidation timing, but that does not reconcile the ex-Bliss figure with the earlier working-capital outlook, creating a material cash-conversion issue for modeling.
Bliss Leadership Continuity Has Changed Without Explanation · 6 November 2026. The May 2026 call explicitly promised that Bliss's current management would continue, while the Aug 2026 call emphasized retaining the acquired businesses' independence and existing management. The Nov 2026 call simultaneously said the team remained the same and disclosed a newly appointed CEO, without explaining whether this supersedes or supplements the prior continuity commitment.
EBITDA Margin Guidance Downgrade · 25 May 2026. In the Oct 2025 call, management confidently projected structural EBITDA margins to stabilize around 25% going forward. However, in the May 2026 call, they quietly walked back this guidance, resetting future expectations to align with "this year's numbers" (FY26 reported EBITDA margin was 23%) without explaining the 200 basis point downgrade.
Every quote above is taken word for word from the company’s own earnings calls.
How much does Anupam Rasayan India earn on its capital?
Anupam Rasayan India Ltd earned a ROCE of 7% in FY26. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 9.4% net margin and 0.30× asset turnover (sales divided by assets).
Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.
Why the return is what it is (FY26): a 9.4% net margin × 0.30× asset turnover × 2.43× leverage (assets divided by equity) ≈ 6.9% on equity. The margin does its share; borrowing is a big part of it.
The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 63% on reported income across 17 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.
Does Anupam Rasayan India have too much debt?
Anupam Rasayan India Ltd had ₹1,867 Cr of borrowings against ₹3,302 Cr of equity in FY26, so its debt is 0.57× its equity. Its operating profit is 4 times its interest bill. Over 5 years borrowings went from ₹423 Cr to ₹1,867 Cr. Over the last 3 of those years it spent ₹1,681 Cr on assets.
Debt-to-equity shows how much of the business is paid for with borrowed money. Interest cover shows how many times operating profit pays the interest bill. Low debt and high cover are the safe combination.
Part of the spending on assets is being paid for with borrowed money.
The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 63% on reported income across 17 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data.
What is the Anupam Rasayan India shareholding pattern?
Promoters cut their stake in Anupam Rasayan India Ltd by 2.2 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 59.1% of the company. Foreign institutions moved +1.7 points over the same period, to 8.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.
Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.
Why this happened. The performance materials segment is Anupam's highest-optionality exposure. 245% YoY growth in 9M FY26 reflects commercialization of contracts signed in FY25, including a Japan multinational MPA for semiconductor-grade molecules and E-Lyte Innovations LOI for electrolyte solutions. The structural tailwind is EV supply chain diversification away from China and data center buildout requiring specialty electronic chemicals. Long customer qualification cycles (3-5 years) mean once validated, the revenue base is sticky.
Over the last two years: Promoters: −2.2 points over 8 quarters, to 59.1%; Foreign institutions: +1.7 points over 8 quarters, to 8.7%; Domestic institutions: +0.0 points over 8 quarters, to 2.3%.
Why the owners changed: promoters drove it (−2.2 points), with the other side taken by foreign institutions (+1.7 points). They reduced their stake.
Watch next
- Metric
- Performance Materials, Defense, Electronics, EV Chemistry
- Threshold
- Q4 FY26 WC days actual (must show progress below 230 days to validate FY27 goal)
- Which result
- the next result
How far is Anupam Rasayan India from balance-sheet trouble?
For Anupam Rasayan India Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.
The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.
How does Anupam Rasayan India rank in its industry?
48.9 out of 100, rank 18 of 30 in Speciality Chemicals, with 82% of the evidence available.
Anupam Rasayan India Ltd scores 48.9 out of 100 against the 30 companies it is compared with in Speciality Chemicals, ranking 18. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
The four parts add up to the total exactly: 19.3 + 11.1 + 8.6 + 9.9 = 48.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here.
What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.
Which companies is Anupam Rasayan India compared with?
Anupam Rasayan India ranks 18 of 30 Speciality Chemicals companies on the 4-Factor Sector Score, with 48.9 out of 100.
- 1Panama Petrochem LtdPANAMAPET · losing its lead · Most evidence points up · 90% evidence77.2out of 100
How the score adds up
Growth & earnings 33.5/35 · Revenue 75% · Profit 100% · Operating margin change 8 points · 100% evidenceCapital efficiency 17.2/25 · ROCE 19.2% (year to Mar 2026) · Operating margin 17.2% · 100% evidenceValuation 14.6/20 · P/E 3.8× · PEG — · 50% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) 12.1% · Strength vs NIFTY 500 (same reading) 15.8% · 1 year 39.7% · 100% evidence · 8 of 12 weeks aheadExact sum: 33.5 + 17.2 + 14.6 + 11.9 = 77.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. - 2Galaxy Surfactants LtdGALAXYSURF · losing its lead · Most evidence points up · 85% evidence67.4out of 100
How the score adds up
Growth & earnings 28.0/35 · Revenue 30.2% · Profit 42.3% · Operating margin change 2 points · 100% evidenceCapital efficiency 11.9/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 10.5% · 100% evidenceValuation 16.2/20 · P/E 19.3× · PEG 1.14 · 100% evidenceRelative strength 11.3/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 6.9% · 1 year 7.5% · 25% evidence · 11 of 12 weeks aheadExact sum: 28 + 11.9 + 16.2 + 11.3 = 67.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 3Black Rose Industries LtdBLACKROSE · quiet · Most evidence points up · 75% evidence66.4out of 100
How the score adds up
Growth & earnings 27.4/35 · Revenue 13% · Profit 65% · Operating margin change 5 points · 100% evidenceCapital efficiency 14.8/25 · ROCE 18.7% (year to Mar 2026) · Operating margin 13.6% · 100% evidenceValuation 14.4/20 · P/E 15.3× · PEG — · 50% evidenceRelative strength 9.8/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 0.6% · 1 year — · 25% evidence · 6 of 12 weeks aheadExact sum: 27.4 + 14.8 + 14.4 + 9.8 = 66.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 4Yasho Industries LtdYASHO · losing its lead · Evidence leans up · 68% evidence64.3out of 100
How the score adds up
Growth & earnings 30.4/35 · Revenue 54.2% · Profit 100% · Operating margin change 3 points · 100% evidenceCapital efficiency 12.6/25 · ROCE 8.9% (year to Mar 2026) · Operating margin 21% · 100% evidenceValuation 9.1/20 · P/E 52.1× · PEG — · 15% evidenceRelative strength 12.2/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 44% · 1 year 126.5% · 25% evidence · 9 of 12 weeks aheadExact sum: 30.4 + 12.6 + 9.1 + 12.2 = 64.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 5Fineotex Chemical LtdFCL · leader · Evidence leans up · 100% evidence61.9out of 100
How the score adds up
Growth & earnings 20.8/35 · Revenue 100% · Profit 68.7% · Operating margin change -8 points · 100% evidenceCapital efficiency 13.8/25 · ROCE 18.3% (year to Mar 2026) · Operating margin 15.5% · 100% evidenceValuation 9.1/20 · P/E 39.9× · PEG 1.13 · 100% evidenceRelative strength 18.2/20 · Strength vs its industry (price vs its 52-week average, weekly) 42.8% · Strength vs NIFTY 500 (same reading) 45.9% · 1 year 81.3% · 100% evidence · 12 of 12 weeks aheadExact sum: 20.8 + 13.8 + 9.1 + 18.2 = 61.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 6Tatva Chintan Pharma Chem LtdTATVA · losing its lead · Evidence leans up · 93% evidence61.1out of 100
How the score adds up
Growth & earnings 28.9/35 · Revenue 49.2% · Profit 100% · Operating margin change 1 points · 100% evidenceCapital efficiency 8.8/25 · ROCE 7.2% (year to Mar 2026) · Operating margin 18.9% · 100% evidenceValuation 10.3/20 · P/E 61.3× · PEG 1.23 · 65% evidenceRelative strength 13.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 11.4% · Strength vs NIFTY 500 (same reading) 15.7% · 1 year 13.8% · 100% evidence · 8 of 12 weeks aheadExact sum: 28.9 + 8.8 + 10.3 + 13.1 = 61.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 7Privi Speciality Chemicals LtdPRIVISCL · quiet · Evidence leans up · 82% evidence60.0out of 100
How the score adds up
Growth & earnings 23.6/35 · Revenue 17.5% · Profit 44.5% · Operating margin change -1 points · 95% evidenceCapital efficiency 18.6/25 · ROCE 22.3% (year to Mar 2026) · Operating margin 26.3% · 76% evidenceValuation 9.8/20 · P/E 36× · PEG — · 50% evidenceRelative strength 8.0/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.5% · Strength vs NIFTY 500 (same reading) 0.9% · 1 year 9.4% · 100% evidence · 0 of 12 weeks aheadExact sum: 23.6 + 18.6 + 9.8 + 8 = 60 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 8Vikram Thermo (India) Ltdbreaking out · Evidence leans up · 72% evidence59.4out of 100
How the score adds up
Growth & earnings 18.8/35 · Revenue 16.9% · Profit 41.9% · Operating margin change -4 points · 95% evidenceCapital efficiency 21.2/25 · ROCE 36.2% (year to Mar 2026) · Operating margin 40.9% · 95% evidenceValuation 7.4/20 · P/E 21.7× · PEG — · 50% evidenceRelative strength 12.0/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 39.3% · 1 year — · 25% evidence · 12 of 12 weeks aheadExact sum: 18.8 + 21.2 + 7.4 + 12 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 9Aarti Industries LtdAARTIIND · losing its lead · Evidence leans up · 100% evidence59.0out of 100
How the score adds up
Growth & earnings 26.4/35 · Revenue 39.8% · Profit 100% · Operating margin change -3 points · 100% evidenceCapital efficiency 9.8/25 · ROCE 6.9% (year to Mar 2026) · Operating margin 11.2% · 100% evidenceValuation 13.7/20 · P/E 28.3× · PEG 0.93 · 100% evidenceRelative strength 9.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -0.6% · Strength vs NIFTY 500 (same reading) 4% · 1 year 20.2% · 100% evidence · 4 of 12 weeks aheadExact sum: 26.4 + 9.8 + 13.7 + 9.1 = 59 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 10Chemcon Speciality Chemicals LtdCHEMCON · breaking out · Evidence leans up · 75% evidence55.4out of 100
How the score adds up
Growth & earnings 24.1/35 · Revenue 22.3% · Profit 20.2% · Operating margin change 4.1 points · 100% evidenceCapital efficiency 8.8/25 · ROCE 6.3% (year to Mar 2026) · Operating margin 16.9% · 100% evidenceValuation 11.3/20 · P/E 23.4× · PEG — · 50% evidenceRelative strength 11.2/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 5.1% · 1 year -12.6% · 25% evidence · 9 of 12 weeks aheadExact sum: 24.1 + 8.8 + 11.3 + 11.2 = 55.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 11Aether Industries LtdAETHER · losing its lead · Evidence leans up · 100% evidence53.8out of 100
- 12Kronox Lab Sciences LtdKRONOX · breaking out · Evidence leans up · 68% evidence53.6out of 100
- 13Paushak LtdPAUSHAKLTD · losing its lead · Evidence leans up · 75% evidence51.5out of 100
- 14Alkyl Amines Chemicals LtdALKYLAMINE · quiet · Evidence leans up · 100% evidence51.0out of 100
- 15Neogen Chemicals LtdNEOGEN · leader · Evidence leans up · 100% evidence50.8out of 100
- 16Platinum Industries LtdPLATIND · turning · Evidence leans down · 75% evidence49.9out of 100
- 17Pidilite Industries LtdPIDILITIND · quiet · Evidence leans down · 100% evidence49.3out of 100
- 18Anupam Rasayan India Ltd this pageANURAS · turning · Evidence leans down · 82% evidence48.9out of 100
How the score adds up
Growth & earnings 19.3/35 · Revenue 23.8% · Profit 5% · Operating margin change 4 points · 95% evidenceCapital efficiency 11.1/25 · ROCE 7.4% (year to Mar 2026) · Operating margin 23.2% · 76% evidenceValuation 8.6/20 · P/E 83.4× · PEG — · 50% evidenceRelative strength 9.9/20 · Strength vs its industry (price vs its 52-week average, weekly) -5.5% · Strength vs NIFTY 500 (same reading) -0.5% · 1 year 6% · 100% evidence · 1 of 12 weeks aheadExact sum: 19.3 + 11.1 + 8.6 + 9.9 = 48.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. - 19Sunshield Chemicals LtdSUNSHIEL · quiet · Evidence leans down · 75% evidence48.2out of 100
- 20Grauer & Weil (India) LtdGRAUWEIL · breaking out · Evidence leans down · 90% evidence46.1out of 100
- 21Amines & Plasticizers LtdAMNPLST · quiet · Evidence leans down · 75% evidence45.7out of 100
- 22DIC India LtdDICIND · Evidence leans down · 70% evidence45.3out of 100
- 23DMCC Speciality Chemicals LtdDMCC · quiet · Evidence leans down · 83% evidence43.4out of 100
- 24Clean Science & Technology LtdCLEAN · quiet · Evidence leans down · 85% evidence43.1out of 100
- 25Vinati Organics LtdVINATIORGA · quiet · Evidence leans down · 82% evidence43.1out of 100
- 26Amal LtdAMAL · quiet · Evidence leans down · 68% evidence43.1out of 100
- 27Innovassynth Technologies (India) Ltdbreaking out · Too little evidence to rank firmly · 57% evidence40.3out of 100
- 28Transpek Industry LtdTRANSPEK · turning · Evidence leans down · 67% evidence38.6out of 100
- 29Vishnu Chemicals LtdVISHNU · losing its lead · Evidence leans down · 90% evidence37.6out of 100
- 30Thirumalai Chemicals LtdTIRUMALCHM · quiet · Most evidence points down · 71% evidence34.0out of 100
Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.
In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.
Related companies: Speciality Chemicals, all 30 compared on one page.
Which companies are close to Anupam Rasayan India in size?
Anupam Rasayan India is the 4th largest of 30 Speciality Chemicals companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Pidilite Industries, Aether Industries and Aarti Industries. Just below it: Privi Speciality Chemicals, Vinati Organics and Neogen Chemicals.
Speciality Chemicals companies close in size
- Pidilite Industries Ltd ₹1,55,857 crore
- Aether Industries Ltd ₹21,865 crore
- Aarti Industries Ltd ₹16,778 crore
- Anupam Rasayan India Ltd ₹15,040 crore
- Privi Speciality Chemicals Ltd ₹13,431 crore
- Vinati Organics Ltd ₹11,906 crore
- Neogen Chemicals Ltd ₹8,352 crore
All 30 Speciality Chemicals companies, largest first
Companies close in size in other industries
- Bayer CropScience Ltd ₹15,064 crore · Pesticides/Agrochemicals
- Swan Defence and Heavy Industries Ltd ₹15,047 crore · Ship - Docks/Breaking/Repairs
- Anupam Rasayan India Ltd ₹15,040 crore
- Clean Max Enviro Energy Solutions Ltd ₹14,977 crore · Power Generation & Supply
- Azad Engineering Ltd ₹14,976 crore · Aerospace & Defence - Equipments
What else do people ask about Anupam Rasayan India?
What is Anupam Rasayan India's share price today?
Anupam Rasayan India Ltd's share price is ₹1,321.10, +6.0% over the past year. The whole company is worth ₹15,036 Cr on the market.
In the last 52 weeks it traded between ₹1,102 to ₹1,376; today it is 80% of the way up from the low, 9.1% above its 200-day average (as of 18 November 2026).
What were Anupam Rasayan India's latest quarterly results?
Anupam Rasayan India Ltd reported revenue of ₹806 Cr and net profit of ₹65.0 Cr for the Sep 2026 quarter. Revenue rose 10.3% and profit rose 14.0% compared with a year earlier. Earnings per share were ₹4.39.
The operating margin was 23.2%, 4.6 percentage points higher than a year earlier (as of 18 November 2026).
What is Anupam Rasayan India's market cap?
Anupam Rasayan India Ltd's market capitalisation is ₹15,036 Cr at a share price of ₹1,321.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026).
How is Anupam Rasayan India performing?
Anupam Rasayan India Ltd's share price has been falling for 7 weeks. In its latest quarter, revenue rose 10.3% and profit rose 14.0% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 2 weeks running (as of 18 November 2026).
Will Anupam Rasayan India's share price go up?
This page does not forecast Anupam Rasayan India Ltd's share price. What it shows instead: the share price is ₹1,321.10, and it has been falling for 7 weeks. Its P/E of 83.4× is higher than 55% of its own last 6 years (as of 18 November 2026).
Who owns Anupam Rasayan India?
Promoters own 59.1% of Anupam Rasayan India Ltd, foreign institutions 8.7%, domestic institutions 2.3% and the public 30.0% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 2.2 percentage points over 8 quarters (as of 18 November 2026).
Does Anupam Rasayan India have too much debt?
Anupam Rasayan India Ltd has a moderate amount of debt: its debt is 0.50× its equity, and its operating profit is 3 times its interest bill. At Sep 2026 borrowings were ₹2,533 Cr against equity of ₹5,048 Cr.
Keep that borrowing in mind when reading the returns on this page (as of 18 November 2026).
Where is Anupam Rasayan India in its business cycle?
Anupam Rasayan India Ltd's FY26 operating margin was 22.2%, against a 12-year range of 18.5% to 28.4%. The latest quarter was 23.2%, the middle of its own range, neither a peak nor a low.
Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026).
What could break the Anupam Rasayan India story?
The main question: promoters moved −2.2 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026).
Is Anupam Rasayan India a stock worth studying right now?
What the numbers show: Anupam Rasayan India Ltd's earnings have grown faster than its share price. Earnings per share grew +16.4% in a year while the price moved +6.0%. The main open question: whether the owners’ moves turn back in line with the business.
Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026).
Is there a Anupam Rasayan India share price forecast for 2026?
What management itself guided: H2FY27 consolidated revenue around ₹2,400-2,500 crore implying ₹4,800-5,000 crore annualized run-rate.
Where do these numbers come from?
Sector Alpha, written by code from the published numbers. Data as of 18 November 2026.
Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.
See the plain-text version of this page.
More lists
Every Sector Alpha list, grouped
Stock screens
Market lists
Themes
Sectors
X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.